U.S. Markets closed

FDA grants Genentech's Perjeta regimen accelerated approval

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration granted accelerated approval of a Perjeta regimen for neoadjuvant treatment in people with high-risk, HER2-positive early stage breast cancer. The Perjeta regimen is the first neoadjuvant breast cancer treatment approved by the FDA and also the first to be approved based on pCR data.